

FDA approval for Zydus's new drug

25 June 2015 | News | By BioSpectrum Bureau

FDA approval for Zydus's new drug



Zydus Cadila has received the final approval from the United States Food and Drug Administration (US FDA) to market Pyridostigmine Bromide Tablets USP, 60 mg.

The estimated sales in 2015 for Pyridostigmine Bromide Tablets USP, used in the treatment of various neurological disorders, is \$27.9 million, as per IMS.

The group now has 100 approvals and has so far filed over 260 ANDAs since the commencement of the filing process in FY 2003-04.